Wolfgang Landgraf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wolfgang Landgraf has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- David R. Owens
Diabetes Research Group Swansea University Wales UK
12 shared publications - Geremia B. Bolli
Department of Medicine and Surgery Perugia University Medical School Perugia Italy
8 shared publications - Brian Murray Frier
The Queen's Medical Research Institute University of Edinburgh Edinburgh UK
7 shared publications Franz Hofmann
Institut für Pharmakologie und Toxikologie, Technischen Universität München, Germany
6 shared publicationsLouise Traylor
Sanofi US, Inc. Bridgewater New Jersey
5 shared publicationsDavid R. Owens
Swansea University, Diabetes Research Group Cymru, College of Medicine, Swansea, UK
4 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
The Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes
Background: Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant Diabetes (SIRD) became the most replicated ones in diabetes cohorts since its introduction in 2018. This review summarises the current evidence gained from the Ahlqvist subphenotypes focusing on distribution patterns, key characteristics, comorbidities and their clinical implementation. Methods: We conducted a narrative literature search of PubMed for English‐language articles published from inception to June 2026 using combinations of the terms ‘k‐means clustering’, ‘classification of diabetes’, ‘ Ahlqvist methodology’, ‘type 2 diabetes’, ‘diabetes subphenotypes’ and ‘diabetes subtypes’. Literature was eligible which reported the same Ahlqvist classification method as originally applied. Results: Twenty‐eight cohorts were identified incorporating more than 97 000 people with diabetes. Ahlqvist subphenotypes have been studied mainly in White/European and East/South Asian populations but seldom in Black/Africans and Hispanic/Latin Americans. MARD and MOD had the highest prevalences among populations; SIDD had severe insulin deficiency and hyperglycaemia, and low fasting C‐peptide (FCP) levels; SIRD was insulin resistant with high FCP levels and incidence risk of nephropathy. Retrospective analyses of glycaemic responses to glucose‐lowering treatments did not clearly favour any drug regimen for subphenotypes. Conclusions: Ahlqvist T2D subphenotypes reflect the heterogeneity of T2D. However, clinical implementation is associated with many barriers, and further studies must prove the value of subphenotype‐guided management of T2D towards precision diabetes.
- 5 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessThe Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes
Background: Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant Diabetes (SIRD) became the most replicated ones in diabetes cohorts since its introduction in 2018. This review summarises the current evidence gained from the Ahlqvist subphenotypes focusing on distribution patterns, key characteristics, comorbidities and their clinical implementation. Methods: We conducted a narrative literature search of PubMed for English‐language articles published from inception to June 2026 using combinations of the terms ‘k‐means clustering’, ‘classification of diabetes’, ‘ Ahlqvist methodology’, ‘type 2 diabetes’, ‘diabetes subphenotypes’ and ‘diabetes subtypes’. Literature was eligible which reported the same Ahlqvist classification method as originally applied. Results: Twenty‐eight cohorts were identified incorporating more than 97 000 people with diabetes. Ahlqvist subphenotypes have been studied mainly in White/European and East/South Asian populations but seldom in Black/Africans and Hispanic/Latin Americans. MARD and MOD had the highest prevalences among populations; SIDD had severe insulin deficiency and hyperglycaemia, and low fasting C‐peptide (FCP) levels; SIRD was insulin resistant with high FCP levels and incidence risk of nephropathy. Retrospective analyses of glycaemic responses to glucose‐lowering treatments did not clearly favour any drug regimen for subphenotypes. Conclusions: Ahlqvist T2D subphenotypes reflect the heterogeneity of T2D. However, clinical implementation is associated with many barriers, and further studies must prove the value of subphenotype‐guided management of T2D towards precision diabetes.
- Open Access
- 3 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 574-583
Importance of targeting post‐prandial hyperglycaemia to achieve HbA1c goals in insulin glargine‐treated subphenotypes of type 2 diabetes
Aims: To explore outcome parameters related to achieving HbA1c goal (n = 2,435) were clustered into T2D subphenotypes, with ≥97% having either Severe Insulin‐Deficient Diabetes (SIDD) (9%–22%), Mild Age‐Related Diabetes (MARD) (8%–18%), or Mild Obesity Diabetes (MOD) (56%–78%) across trials. Subphenotypes were stratified by HbA1c goal achievement (HbA1c <7.0%/responders or ≥7.0%/non‐responders), and efficacy and safety parameters were analysed both at baseline and after 26 weeks. Glargine groups were pooled. Results: With all basal insulin regimens, the responders were fewest in SIDD (19%–33%), followed by MOD (33%–56%) and MARD (42%–62%). Mean FPG at 26 weeks was slightly lower in responders (103–128 mg/dL; 5.8–7.1 mmol/L) compared to non‐responders (124–143 mg/dL; 6.9–7.9 mmol/L) in each subphenotype, despite equivalent or higher mean glargine doses in non‐responders. Self‐monitored post‐prandial glucose (PPG) was consistently above the recommended target of 140 mg/dL (7.8 mmol/L) in non‐responders, even in those on intensified insulin treatment. Hypoglycaemia risk was similar or only slightly increased in responders compared to non‐responders across subphenotypes. Conclusions: With glargine‐based regimens, strict control of PPG is necessary to attain HbA1c <7.0% across all T2D subphenotypes. Therefore, to achieve optimal treatment goals, especially in the SIDD subphenotype, appropriate dose adjustments of both basal and preprandial insulin are required.
- 3 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 574-583
Open AccessImportance of targeting post‐prandial hyperglycaemia to achieve HbA1c goals in insulin glargine‐treated subphenotypes of type 2 diabetes
Aims: To explore outcome parameters related to achieving HbA1c goal (n = 2,435) were clustered into T2D subphenotypes, with ≥97% having either Severe Insulin‐Deficient Diabetes (SIDD) (9%–22%), Mild Age‐Related Diabetes (MARD) (8%–18%), or Mild Obesity Diabetes (MOD) (56%–78%) across trials. Subphenotypes were stratified by HbA1c goal achievement (HbA1c <7.0%/responders or ≥7.0%/non‐responders), and efficacy and safety parameters were analysed both at baseline and after 26 weeks. Glargine groups were pooled. Results: With all basal insulin regimens, the responders were fewest in SIDD (19%–33%), followed by MOD (33%–56%) and MARD (42%–62%). Mean FPG at 26 weeks was slightly lower in responders (103–128 mg/dL; 5.8–7.1 mmol/L) compared to non‐responders (124–143 mg/dL; 6.9–7.9 mmol/L) in each subphenotype, despite equivalent or higher mean glargine doses in non‐responders. Self‐monitored post‐prandial glucose (PPG) was consistently above the recommended target of 140 mg/dL (7.8 mmol/L) in non‐responders, even in those on intensified insulin treatment. Hypoglycaemia risk was similar or only slightly increased in responders compared to non‐responders across subphenotypes. Conclusions: With glargine‐based regimens, strict control of PPG is necessary to attain HbA1c <7.0% across all T2D subphenotypes. Therefore, to achieve optimal treatment goals, especially in the SIDD subphenotype, appropriate dose adjustments of both basal and preprandial insulin are required.
- Open Access
- 15 June 2024
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (8) , 1769-1784
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis
Introduction This study aimed to evaluate glycemic outcomes in subphenotypes of type 2 diabetes (T2D) with HbA1c > 7.0%, previously on basal insulin (pre-BI) alone (≥ 42 U/day) or on basal-bolus therapy (pre-BB), and who were switched to either basal insulin glargine 300 U/mL (IGlar-300) or 100 U/mL (IGlar-100), with or without pre-prandial insulin. Methods Participants from EDITION 2 (pre-BI, n = 785), and EDITION 1 (pre-BB, n = 792) trials were assigned retrospectively to subphenotypes of T2D: severe insulin deficient diabetes (SIDD), mild age-related diabetes (MARD), mild obesity diabetes (MOD), and severe insulin resistant diabetes (SIRD). Key efficacy and safety parameters were analyzed at baseline, and after 26 weeks, for IGlar-300 and IGlar-100 pooled groups according to subphenotypes. Outcomes were also compared with insulin-naïve subphenotypes on oral antihyperglycemic drugs (OADs) from the EDITION 3 trial (pre-OAD, n = 858). Results Pre-BI and pre-BB treated subphenotypes with SIDD had a higher mean HbA1c (8.9% and 9.1%) at baseline compared to those of MARD (7.7% and 7.8%) and MOD (8.1% and 8.2%) and after 26 weeks remained above target HbA1c (7.7% and 8.0%) despite mean glargine doses of 0.7 to 1.0 U/kg/day and pre-prandial insulin use in the pre-BB SIDD subgroup. Pre-BB treated individuals with MARD and MOD achieved lower HbA1c levels (6.9% and 7.2%) than the pre-BI groups (7.3% and 7.5%) despite similar mean FPG levels (123–130 mg/dL). Only 19–22% of participants with SIDD achieved HbA1c < 7.0% compared to 33–51% with MARD and MOD, respectively. Pre-BI and pre-BB treated subphenotypes experienced more hypoglycemia than pre-OAD treated subphenotypes. Conclusion Individuals with T2D assigned post hoc to the SIDD subphenotype achieved suboptimal glycemic control with glargine regimens including basal-bolus therapy, alerting clinicians to improve further diabetes treatment, particularly post-prandial glycemic control, in individuals with SIDD.
- 15 June 2024
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (8) , 1769-1784
Open AccessResponses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis
Introduction This study aimed to evaluate glycemic outcomes in subphenotypes of type 2 diabetes (T2D) with HbA1c > 7.0%, previously on basal insulin (pre-BI) alone (≥ 42 U/day) or on basal-bolus therapy (pre-BB), and who were switched to either basal insulin glargine 300 U/mL (IGlar-300) or 100 U/mL (IGlar-100), with or without pre-prandial insulin. Methods Participants from EDITION 2 (pre-BI, n = 785), and EDITION 1 (pre-BB, n = 792) trials were assigned retrospectively to subphenotypes of T2D: severe insulin deficient diabetes (SIDD), mild age-related diabetes (MARD), mild obesity diabetes (MOD), and severe insulin resistant diabetes (SIRD). Key efficacy and safety parameters were analyzed at baseline, and after 26 weeks, for IGlar-300 and IGlar-100 pooled groups according to subphenotypes. Outcomes were also compared with insulin-naïve subphenotypes on oral antihyperglycemic drugs (OADs) from the EDITION 3 trial (pre-OAD, n = 858). Results Pre-BI and pre-BB treated subphenotypes with SIDD had a higher mean HbA1c (8.9% and 9.1%) at baseline compared to those of MARD (7.7% and 7.8%) and MOD (8.1% and 8.2%) and after 26 weeks remained above target HbA1c (7.7% and 8.0%) despite mean glargine doses of 0.7 to 1.0 U/kg/day and pre-prandial insulin use in the pre-BB SIDD subgroup. Pre-BB treated individuals with MARD and MOD achieved lower HbA1c levels (6.9% and 7.2%) than the pre-BI groups (7.3% and 7.5%) despite similar mean FPG levels (123–130 mg/dL). Only 19–22% of participants with SIDD achieved HbA1c < 7.0% compared to 33–51% with MARD and MOD, respectively. Pre-BI and pre-BB treated subphenotypes experienced more hypoglycemia than pre-OAD treated subphenotypes. Conclusion Individuals with T2D assigned post hoc to the SIDD subphenotype achieved suboptimal glycemic control with glargine regimens including basal-bolus therapy, alerting clinicians to improve further diabetes treatment, particularly post-prandial glycemic control, in individuals with SIDD.
- Open Access
- 20 October 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 503-511
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial
Introduction: To compare responses to basal insulin glargine 300 U/ml (IGlar‐300) and 100 U/ml (IGlar‐100) in newly defined subphenotypes of type 2 diabetes. Methods: Insulin‐naive participants (n = 858) from the EDITION 3 trial were assigned to subphenotypes ‘Mild Age‐Related Diabetes (MARD)’, ‘Mild Obesity Diabetes (MOD)’, ‘Severe Insulin Resistant Diabetes (SIRD)’ and ‘Severe Insulin Deficient Diabetes (SIDD)’. Key variables were analysed at baseline and 26 weeks. Results: Participants were comprised of MOD 56.1% (n = 481), SIDD 22.1% (n = 190), MARD 18.2% (n = 156) and SIRD 3.0% (n = 26). After 26 weeks a similar decrease in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) of 16‐19 mmol/mol and 1.4‐1.7 mmol/L, respectively, occurred in MARD and MOD with both insulins. SIDD had the most elevated HbA1c and FPG (80‐83 mmol/mol/11.1‐11.4 mmol/L) and reduction in both HbA1c and FPG was greater with IGlar‐100 than with IGlar‐300 (−18 vs. −15 mmol/mol and −1.6 vs. −1.3 mmol/L, respectively; each p = .03). In SIDD, despite receiving the highest basal insulin doses, HbA1c decline (57‐60 mmol/mol/7.3‐7.6%) was suboptimal at week 26. In MOD and SIDD lower incidences with IGlar‐300 were found for level 1 nocturnal hypoglycaemia [odds ratio (OR) 0.59, 95% confidence intervals (CI) 0.36‐0.97; OR 0.49, 95% CI 0.24‐0.99]. In addition, fewer level 2 hypoglycaemia episodes occurred at any time with IGlar‐300 in SIDD (OR 0.31, 95% CI 0.13‐0.77). Conclusion: Both insulins produce comparable outcomes in type 2 diabetes subphenotypes, but in SIDD, add‐on treatment to basal insulin is required to achieve glycaemic targets.
- 20 October 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (2) , 503-511
Open AccessTreatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial
Introduction: To compare responses to basal insulin glargine 300 U/ml (IGlar‐300) and 100 U/ml (IGlar‐100) in newly defined subphenotypes of type 2 diabetes. Methods: Insulin‐naive participants (n = 858) from the EDITION 3 trial were assigned to subphenotypes ‘Mild Age‐Related Diabetes (MARD)’, ‘Mild Obesity Diabetes (MOD)’, ‘Severe Insulin Resistant Diabetes (SIRD)’ and ‘Severe Insulin Deficient Diabetes (SIDD)’. Key variables were analysed at baseline and 26 weeks. Results: Participants were comprised of MOD 56.1% (n = 481), SIDD 22.1% (n = 190), MARD 18.2% (n = 156) and SIRD 3.0% (n = 26). After 26 weeks a similar decrease in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) of 16‐19 mmol/mol and 1.4‐1.7 mmol/L, respectively, occurred in MARD and MOD with both insulins. SIDD had the most elevated HbA1c and FPG (80‐83 mmol/mol/11.1‐11.4 mmol/L) and reduction in both HbA1c and FPG was greater with IGlar‐100 than with IGlar‐300 (−18 vs. −15 mmol/mol and −1.6 vs. −1.3 mmol/L, respectively; each p = .03). In SIDD, despite receiving the highest basal insulin doses, HbA1c decline (57‐60 mmol/mol/7.3‐7.6%) was suboptimal at week 26. In MOD and SIDD lower incidences with IGlar‐300 were found for level 1 nocturnal hypoglycaemia [odds ratio (OR) 0.59, 95% confidence intervals (CI) 0.36‐0.97; OR 0.49, 95% CI 0.24‐0.99]. In addition, fewer level 2 hypoglycaemia episodes occurred at any time with IGlar‐300 in SIDD (OR 0.31, 95% CI 0.13‐0.77). Conclusion: Both insulins produce comparable outcomes in type 2 diabetes subphenotypes, but in SIDD, add‐on treatment to basal insulin is required to achieve glycaemic targets.
- Open Access
- 13 June 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2495-2504
Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics
Aim: To compare the efficacy and safety of insulin glargine‐300 once daily (Gla‐300) with insulin degludec/aspart (IDegAsp) once daily in patients with type 2 diabetes (T2D) inadequately controlled on oral anti‐diabetic drugs (OADs). Materials and methods: A systematic literature review of randomized controlled trials was followed by an indirect treatment comparison of studies involving insulin naïve adults, inadequately controlled [glycated haemoglobin (HbA1c) ≥7.0%] on OADs, who received Gla‐300 or IDegAsp once daily. Outcomes of interest were change in HbA1c, blood glucose, weight and insulin dose, as well as incidence and event rate of hypoglycaemia and other adverse events. Results: Four trials with broadly similar baseline patient characteristics were included in the meta‐analyses and indirect treatment comparison. At 24‐28 weeks, the indirect comparison of Gla‐300 to IDegAsp once daily estimated no statistically significant difference for change in HbA1c (%) from baseline [mean difference of 0.10% (95% CI: −0.20, 0.39; p = .52)]; a statistically significant mean difference of −1.31 kg (95% CI: −1.97, −0.65; p < .05) for change in body weight from baseline; statistically significant odds ratios of 0.62 (95% CI: 0.41, 0.93; p < .05) for incidence of any hypoglycaemia; and 0.47 (95% CI: 0.25, 0.87; p < .05) for incidence of anytime confirmed hypoglycaemia (plasma glucose <3.0‐3.1 mmol/L). No significant differences were observed for insulin dose and adverse events. Conclusion: In insulin‐naïve patients with T2D inadequately controlled on OADs, commencing Gla‐300 shows a comparable HbA1c reduction, but with significantly less weight gain and a lower incidence of any and confirmed hypoglycaemia compared with commencing IDegAsp.
- 13 June 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2495-2504
Open AccessComparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics
Aim: To compare the efficacy and safety of insulin glargine‐300 once daily (Gla‐300) with insulin degludec/aspart (IDegAsp) once daily in patients with type 2 diabetes (T2D) inadequately controlled on oral anti‐diabetic drugs (OADs). Materials and methods: A systematic literature review of randomized controlled trials was followed by an indirect treatment comparison of studies involving insulin naïve adults, inadequately controlled [glycated haemoglobin (HbA1c) ≥7.0%] on OADs, who received Gla‐300 or IDegAsp once daily. Outcomes of interest were change in HbA1c, blood glucose, weight and insulin dose, as well as incidence and event rate of hypoglycaemia and other adverse events. Results: Four trials with broadly similar baseline patient characteristics were included in the meta‐analyses and indirect treatment comparison. At 24‐28 weeks, the indirect comparison of Gla‐300 to IDegAsp once daily estimated no statistically significant difference for change in HbA1c (%) from baseline [mean difference of 0.10% (95% CI: −0.20, 0.39; p = .52)]; a statistically significant mean difference of −1.31 kg (95% CI: −1.97, −0.65; p < .05) for change in body weight from baseline; statistically significant odds ratios of 0.62 (95% CI: 0.41, 0.93; p < .05) for incidence of any hypoglycaemia; and 0.47 (95% CI: 0.25, 0.87; p < .05) for incidence of anytime confirmed hypoglycaemia (plasma glucose <3.0‐3.1 mmol/L). No significant differences were observed for insulin dose and adverse events. Conclusion: In insulin‐naïve patients with T2D inadequately controlled on OADs, commencing Gla‐300 shows a comparable HbA1c reduction, but with significantly less weight gain and a lower incidence of any and confirmed hypoglycaemia compared with commencing IDegAsp.
- Open Access
- 2 May 2023
- Published by Elsevier in Primary Care Diabetes
- Vol. 17 (4) , 379-385
Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials
- 2 May 2023
- Published by Elsevier in Primary Care Diabetes
- Vol. 17 (4) , 379-385
Open AccessResponse to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials
- Open Access
- 18 July 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 190, 110012
Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants
- 18 July 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 190, 110012
Open AccessDistribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants
- Open Access
- 21 April 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (9) , 1664-1669
Hypoglycaemia risk with insulin glargine 300 U/ mL compared with glargine 100 U/ mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
The relationship between baseline fasting C‐peptide (FCP) and glucose control was examined in insulin‐naïve people with type 2 diabetes inadequately controlled with oral antihyperglycaemic drugs commencing basal insulin glargine 300 U/mL (Gla‐300) or 100 U/mL (Gla‐100) in the absence of sulfonylurea/glinides. Participants with FCP measurement from the EDITION 3 trial (n = 867) were stratified according to baseline FCP (≤0.40, >0.40‐1.20, >1.20 nmol/L); 11.0%, 70.9% and 18.1% contributed to each group. Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 26 weeks. Glycaemic control (HbA1c, FPG) at 26 weeks was similar in each FCP group between insulins. However, end‐of‐study insulin dose was greater with higher FCP for both insulins. More people with lower baseline FCP experienced hypoglycaemia with both insulins, but with numerically lower incidence for Gla‐300 versus Gla‐100 across all FCP groups for all definitions (time periods and levels) of hypoglycaemia. This suggests that Gla‐300 might be particularly advantageous for people who are at higher risk of hypoglycaemia.
- 21 April 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (9) , 1664-1669
Open AccessHypoglycaemia risk with insulin glargine 300 U/ mL compared with glargine 100 U/ mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
The relationship between baseline fasting C‐peptide (FCP) and glucose control was examined in insulin‐naïve people with type 2 diabetes inadequately controlled with oral antihyperglycaemic drugs commencing basal insulin glargine 300 U/mL (Gla‐300) or 100 U/mL (Gla‐100) in the absence of sulfonylurea/glinides. Participants with FCP measurement from the EDITION 3 trial (n = 867) were stratified according to baseline FCP (≤0.40, >0.40‐1.20, >1.20 nmol/L); 11.0%, 70.9% and 18.1% contributed to each group. Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 26 weeks. Glycaemic control (HbA1c, FPG) at 26 weeks was similar in each FCP group between insulins. However, end‐of‐study insulin dose was greater with higher FCP for both insulins. More people with lower baseline FCP experienced hypoglycaemia with both insulins, but with numerically lower incidence for Gla‐300 versus Gla‐100 across all FCP groups for all definitions (time periods and levels) of hypoglycaemia. This suggests that Gla‐300 might be particularly advantageous for people who are at higher risk of hypoglycaemia.
- 13 October 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (3) , 315-323
Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL
Aim: To examine the relationship between baseline fasting C‐peptide (FCP) and outcomes in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL (Gla‐100). Materials and methods: Post hoc pooled analysis of nine randomized, treat‐to‐target trials in patients with type 2 diabetes inadequately controlled on oral antihyperglycaemic drugs initiating once‐daily Gla‐100. Participants (n = 2165) were stratified at baseline according to FCP (≤0.40, >0.40–1.20, >1.20–2.00, >2.00 nmol/L). Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 24 weeks. Results: At baseline low FCP levels were associated with longer known diabetes duration, lower body mass index and higher fasting plasma glucose (FPG). Following Gla‐100 introduction, the mean HbA1c reduction at week 24 was similar in all four FCP groups, albeit fewer people in the lowest FCP group achieved HbA1c 0.40 nmol/L. By contrast, FPG reduction and proportion reaching FPG ≤5.6 mmol/L were greatest in the lowest FCP group, diminishing at higher FCP levels. Gla‐100 dose at week 24 was lowest in the ≤0.40 nmol/L FCP group and highest in the >1.20 nmol/L FCP group. Incidence and event rate of overall, nocturnal and severe hypoglycaemia were higher at week 24 in groups with lower FCP levels. In multivariable regression analysis baseline FCP, concomitant sulphonylurea use and endpoint HbA1c were strong predictors of hypoglycaemia. Conclusions: FCP levels identified patients with type 2 diabetes experiencing different responses to basal insulin Gla‐100. A low FCP identifies a markedly insulin‐deficient, insulin‐sensitive subgroup/phenotype with an enhanced risk of hypoglycaemia, which requires a low initial basal insulin dose, cautious titration and earlier addition of prandial glucose‐lowering therapy.
- 13 October 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (3) , 315-323
Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL
Aim: To examine the relationship between baseline fasting C‐peptide (FCP) and outcomes in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL (Gla‐100). Materials and methods: Post hoc pooled analysis of nine randomized, treat‐to‐target trials in patients with type 2 diabetes inadequately controlled on oral antihyperglycaemic drugs initiating once‐daily Gla‐100. Participants (n = 2165) were stratified at baseline according to FCP (≤0.40, >0.40–1.20, >1.20–2.00, >2.00 nmol/L). Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 24 weeks. Results: At baseline low FCP levels were associated with longer known diabetes duration, lower body mass index and higher fasting plasma glucose (FPG). Following Gla‐100 introduction, the mean HbA1c reduction at week 24 was similar in all four FCP groups, albeit fewer people in the lowest FCP group achieved HbA1c 0.40 nmol/L. By contrast, FPG reduction and proportion reaching FPG ≤5.6 mmol/L were greatest in the lowest FCP group, diminishing at higher FCP levels. Gla‐100 dose at week 24 was lowest in the ≤0.40 nmol/L FCP group and highest in the >1.20 nmol/L FCP group. Incidence and event rate of overall, nocturnal and severe hypoglycaemia were higher at week 24 in groups with lower FCP levels. In multivariable regression analysis baseline FCP, concomitant sulphonylurea use and endpoint HbA1c were strong predictors of hypoglycaemia. Conclusions: FCP levels identified patients with type 2 diabetes experiencing different responses to basal insulin Gla‐100. A low FCP identifies a markedly insulin‐deficient, insulin‐sensitive subgroup/phenotype with an enhanced risk of hypoglycaemia, which requires a low initial basal insulin dose, cautious titration and earlier addition of prandial glucose‐lowering therapy.
- Open Access
- 6 December 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (2) , 321-329
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%
Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c) target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes mellitus (T2DM). Materials and methods: Post‐hoc pooled analysis of 16 randomized, treat‐to‐target trials involving individuals with T2DM inadequately controlled with oral anti‐hyperglycaemic drugs (n = 3415) initiated on once‐daily insulin glargine 100 U/mL (Gla‐100). Clinical outcomes were assessed by HbA1c response at 24 weeks and individuals were classified as “good responders” with HbA1c <7.0% (<53 mmol/mol) or as “poor responders” with HbA1c ≥7.0% (≥53 mmol/mol). Univariable and multivariable stepwise logistic regression analyses were performed to identify predictive factors for attaining HbA1c <7.0%. Results: Lower levels of baseline HbA1c, fasting plasma glucose (FPG) and post‐prandial plasma glucose (PPG), higher body mass index (BMI), shorter diabetes duration and male sex were associated with a good glycaemic response, but not age or baseline C‐peptide levels. Gla‐100 dose (U/kg) was highest in the poor‐responder group, which had the fewest hypoglycaemia episodes. Univariable analysis for achievement of HbA1c <7.0% confirmed these observations. Multivariable analysis retained baseline HbA1c, body weight, BMI, sex, 2‐hours PPG and diabetes duration as predictors of a good response. Continued use of sulfonylureas, hypoglycaemia and change in body weight were indicative of poor response. Conclusions: Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0% by supplementary Gla‐100 therapy, while sex and BMI were also useful indicators. However, age and C‐peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin.
- 6 December 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (2) , 321-329
Open AccessCommencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%
Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c) target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes mellitus (T2DM). Materials and methods: Post‐hoc pooled analysis of 16 randomized, treat‐to‐target trials involving individuals with T2DM inadequately controlled with oral anti‐hyperglycaemic drugs (n = 3415) initiated on once‐daily insulin glargine 100 U/mL (Gla‐100). Clinical outcomes were assessed by HbA1c response at 24 weeks and individuals were classified as “good responders” with HbA1c <7.0% (<53 mmol/mol) or as “poor responders” with HbA1c ≥7.0% (≥53 mmol/mol). Univariable and multivariable stepwise logistic regression analyses were performed to identify predictive factors for attaining HbA1c <7.0%. Results: Lower levels of baseline HbA1c, fasting plasma glucose (FPG) and post‐prandial plasma glucose (PPG), higher body mass index (BMI), shorter diabetes duration and male sex were associated with a good glycaemic response, but not age or baseline C‐peptide levels. Gla‐100 dose (U/kg) was highest in the poor‐responder group, which had the fewest hypoglycaemia episodes. Univariable analysis for achievement of HbA1c <7.0% confirmed these observations. Multivariable analysis retained baseline HbA1c, body weight, BMI, sex, 2‐hours PPG and diabetes duration as predictors of a good response. Continued use of sulfonylureas, hypoglycaemia and change in body weight were indicative of poor response. Conclusions: Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0% by supplementary Gla‐100 therapy, while sex and BMI were also useful indicators. However, age and C‐peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin.